Related Experiment Video
Updated: Jul 23, 2026
Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Cardiac effects of combination therapy in hypertension
1Department of Internal Medicine, Ochsner Clinic, New Orleans, Louisiana 70121, USA.
Insights
Combination therapy for hypertension, often necessary, requires careful drug selection. Angiotensin-converting enzyme inhibitors with calcium antagonists may reduce left ventricular hypertrophy, while other combinations address specific patient needs.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Hypertension management frequently necessitates multiple drugs.
- Most cardiovascular drug studies focus on monotherapy, limiting combination therapy knowledge.
- Combination therapy insights are often extrapolated from monotherapy data.
Purpose of the Study:
- To review the efficacy of antihypertensive drug combinations.
- To guide selection of drug combinations for specific cardiovascular conditions.
- To highlight potential benefits and drawbacks of combining antihypertensive agents.
Main Methods:
- Literature review of antihypertensive combination therapy.
- Analysis of drug interactions and effects on cardiovascular parameters.
- Evaluation of combination therapy in specific patient populations (e.g., left ventricular hypertrophy, dysfunction, post-myocardial ischemia).
Main Results:
- Angiotensin-converting enzyme inhibitors plus calcium antagonists may reduce left ventricular hypertrophy.
- Combinations stimulating renin-angiotensin or sympathetic systems may not reduce left ventricular hypertrophy.
- Beta-blockers with angiotensin-converting enzyme inhibitors are recommended for hypertensive patients with left ventricular dysfunction.
- Verapamil and angiotensin-converting enzyme inhibitors may reduce reinfarction rates post-myocardial ischemia.
- Angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers can mitigate diuretic side-effects.
Conclusions:
- Combination therapy in hypertension requires strategic selection based on patient pathophysiology.
- Not all beneficial monotherapies translate to equally beneficial combinations.
- Specific combinations can counteract pathophysiologic cascades in complex hypertensive patients.
Abstract:
Control of hypertension and treatment of concomitant pathophysiologic conditions require use of multiple drugs in more than half of all patients. Unfortunately, most studies dealing with cardiovascular effects of antihypertensive drugs have focused on monotherapy. Thus, our knowledge of combination therapy in the treatment of hypertension is, to a great extent, extrapolation from monotherapy. Angiotensin-converting enzyme inhibitors in combination with calcium antagonists should be particularly efficacious in reducing left ventricular hypertrophy. Drug classes that either stimulate the renin-angiotensin system or the sympathetic nervous system are less likely to reduce left ventricular hypertrophy and should be avoided. In hypertensive patients with left ventricular dysfunction, beta-blockers should be combined with angiotensin-converting enzyme inhibitor, whereas in the postmyocardial ischemia patient, verapamil and angiotensin-converting enzyme inhibitors may exert some additional beneficial effects with regard to reinfarction rates. Some of the undesirable metabolic side-effects of diuretics can be mitigated by the addition of an angiotensin-converting enzyme inhibitor or an angiotensin-receptor blocker. Given that two drugs when used separately are beneficial in a disorder does not necessarily mean that their combination is equally or even more beneficial. Sometimes combination therapy is used to counteract different limbs of pathophysiologic cascade operative in hypertensive patients with complications or comorbidities.
Related Concept Videos
01:27Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
01:22Heart Failure Drugs: Diuretics
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:22Heart Failure Drugs: β-Blockers
01:30Heart Failure V: Medical Management
01:28Hypertension IV: Drug Therapy and Lifestyle Modifications